Navigation Links
Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
Date:5/6/2008

X

after three months of therapy or sooner if significant neurotoxicity

develops (Grade 3 or greater). Nephrotoxicities and ototoxicities

were rare and mild.

Based on this promising data, in November 2007 we initiated a

randomized, Phase 2 study comparing picoplatin to oxaliplatin, both

in combination with 5-fluorouracil and leucovorin. We announced

today that we completed the Phase 2 enrollment. This randomized,

controlled 100-patient trial is designed to compare the safety and

efficacy of picoplatin given once every four weeks in combination

with full-dose 5-fluorouracil and leucovorin dosing in the FOLPI

regimen to oxaliplatin in combination with 5-fluorouracil and

leucovorin in the modified FOLFOX-6 regimen.

We currently are on track to generate data from this trial

throughout 2008 and beyond, and will be presenting early Phase 2 and

updated Phase 1 data at ASCO in June this year.

* Prostate Cancer: At the February 2008 ASCO Genitourinary Cancers

Symposium, we reported encouraging safety and efficacy data from our

Phase 1 dose-escalation study of picoplatin in combination with

docetaxel and prednisone in patients with hormone refractory

prostate cancer (HRPC). Picoplatin was safely administered in

combination with full-dose docetaxel and prednisone, the current

standard of care for first-line HRPC patients. The follow-up Phase 2

study completed enrollment late 2007 and we plan to present data

from this study at ASCO this June and at other scientific meetings.

* Oral Picoplatin: In April this year, results were presented from the

ongoing Phase 1 clinical trial of oral picoplatin in patients with

advanced solid tumor malignancies at the Annual Mee
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Poniard Pharmaceuticals Announces Upcoming Conference Participation
2. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
5. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
6. Onyx Pharmaceuticals Reports 2008 First Quarter Results
7. SGX Pharmaceuticals Schedules Teleconference and Webcast to Discuss First Quarter 2008 Results and Provide Pipeline Update
8. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
9. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
10. Keryx Biopharmaceuticals to Present at the Deutsche Bank 33rd Annual Health Care Conference
11. GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Massachusetts (PRWEB) October 22, 2014 ... announced the release of a new infographic, Understanding ... to create a beautifully designed, easy to follow informative ... transmission, areas of outbreak, symptoms and prevention. , "As ... discovered that the 2014 Ebola outbreak represents not only ...
(Date:10/22/2014)... October 22, 2014 Grace Century, a ... healthcare projects, announces the addition of Dr. Yousef ... its advisory team. Dr. Siddiqui will provide further healthcare ... A graduate of University College Medical School ... in medicine in 2001. With further certification as a ...
(Date:10/22/2014)...   Synthetic Biologics, Inc. (NYSE MKT: SYN), ... infections and diseases, announced today that the U.S. Patent ... for a composition of matter patent application that covers ... SYN-004. This is Synthetic Biologics, first allowed patent application ... to the Company,s extensive C. difficile patent ...
(Date:10/22/2014)... 2014 Research and Markets  has announced ... Material, by Application, Geography - Global Analysis and Forecast ... Organic electronics, also called as polymer electronics ... which deals with small conductive molecules and electrically conductive ... and polymers are carbon based, made using synthetic strategies ...
Breaking Biology Technology:Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3
... today,announced strong revenue growth and stable net profits despite ... in the US was offset by a strong,performance from ... Darwazah, said "The US operations, in 2007, reported,operating profit ... loss there so in spite of,this $30m plus loss ...
... BioPharma Corp. (TSX, FSE: "HBP") today announced financial results for the second ... , , , ... U.S. Securities and Exchange Commission which became effective on March 12, 2009 ... , Helix received regulatory approval to ...
... TauTaTis, Inc. announces that its lead compound for inhibition ... Alzheimer,s Disease, has been recognized as the most potent ... LRRK2 reported to date. Mutations of this gene ... most genetic frequent cause of Parkinson,s Disease.TauTaTis, lead compound ...
Cached Biology Technology:Helix BioPharma Announces Q2 2009 Financial Results 2Helix BioPharma Announces Q2 2009 Financial Results 3Helix BioPharma Announces Q2 2009 Financial Results 4Helix BioPharma Announces Q2 2009 Financial Results 5Helix BioPharma Announces Q2 2009 Financial Results 6Helix BioPharma Announces Q2 2009 Financial Results 7Helix BioPharma Announces Q2 2009 Financial Results 8Helix BioPharma Announces Q2 2009 Financial Results 9Helix BioPharma Announces Q2 2009 Financial Results 10Helix BioPharma Announces Q2 2009 Financial Results 11Helix BioPharma Announces Q2 2009 Financial Results 12TauTaTis Discovers Potent Inhibitor of Parkinson's Disease Gene Activity 2
(Date:10/16/2014)... Virginia Institute of Marine Science have received a ... to identify the streams and wetlands most vulnerable ... help local governments and citizens conserve these important ... dataset of tidal-marsh observations first gathered by VIMS ... baseline can today,s researchers accurately map the slow ...
(Date:10/16/2014)... tract infections and worldwide claims the lives of ... Ghent University have succeeded in developing a promising ... , Xavier Saelens (VIB/UGent): "We discovered a ... the development of a novel approach to vaccination ... numerous small children and elderly people." , ...
(Date:10/15/2014)... As our ability to assess the pandemic risk from ... developments, we must not allow ourselves to become complacent ... an international consortium of scientists. , Influenza pandemics arise ... have yet to develop widespread immunity – spreads in ... in the past 100 years, the worst of which ...
Breaking Biology News(10 mins):EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3New perspectives for development of an RSV vaccine 2Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2
... skates (skates made of animal bones) are the oldest ... BC. Why people started skating on ice and where ... in several locations spread across Central and North Europe. ... Journal of the Linnean Society of London, Dr Formenti ...
... not immediately engage in a race against time to save ... the global warming and acidification predicted for later this century. ... from around the world in a major new study published ... the public understands that the lack of sustainability in the ...
... MD The Biophysical Society has announced the winners of ... of the Biophysical Society and the International Biophysics Congress ... of this competitive award are selected based on scientific ... a paper at the conference. Each awardee receives ...
Cached Biology News:Major study concludes that global warming is killing off coral 2Biophysical Society announces winners of 2008 Student Travel Awards 2Biophysical Society announces winners of 2008 Student Travel Awards 3Biophysical Society announces winners of 2008 Student Travel Awards 4Biophysical Society announces winners of 2008 Student Travel Awards 5
Immunogen: MBP-fusion protein of the C-terminal region of the a2 subunit (amino acids K581-D670) Storage: -20 C, Avoid Freeze/Thaw Cycles...
... This antibody recognizes murine IRF7 ... with other related IRF proteins. ... murine IRF7 protein was confirmed ... the 293T cells transfected with ...
... Clone/PAD: PS603. Immunogen: Synthetic ... surrounding the phosphorylated Ser603 residue ... Specificity: Specific for synapsin I ... 3). Reactivity: Rat (positive ...
MMP-20 Immunogen: Activated recombinant human MMP-2 Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: